[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @BPharmCatalyst BioPharmCatalyst BioPharmCatalyst posts on X about $cmnd, $plrz, $capr, $modd the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::56121651/interactions)  - X Week XXXXX +23% - X Month XXXXXX -XX% - X Months XXXXXXXXX +56% - X Year XXXXXXXXX -XX% ### Mentions: XX [#](/creator/twitter::56121651/posts_active)  - X Week XX -XX% - X Month XX -XX% - X Months XXX +19% - X Year XXX +8.50% ### Followers: XXXXXX [#](/creator/twitter::56121651/followers)  - X Week XXXXXX +0.11% - X Month XXXXXX +0.09% - X Months XXXXXX +3.50% - X Year XXXXXX +5.40% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::56121651/influencer_rank)  ### Social Influence **Social category influence** [cryptocurrencies](/list/cryptocurrencies) XX% [stocks](/list/stocks) XX% [finance](/list/finance) XX% [technology brands](/list/technology-brands) X% **Social topic influence** [$cmnd](/topic/$cmnd) #1, [$plrz](/topic/$plrz) #31, [$capr](/topic/$capr) #31, [$modd](/topic/$modd) #1, [$dare](/topic/$dare) #1, [$pmn](/topic/$pmn) #3, [$envb](/topic/$envb) #1, [$nivf](/topic/$nivf) #2, [$clsd](/topic/$clsd) 10%, [$adtx](/topic/$adtx) XX% **Top accounts mentioned or mentioned by** [@artsstocks](/creator/undefined) **Top assets mentioned** [uniQure N.V. (QURE)](/topic/$qure) [Marblex (MBX)](/topic/$mbx) [Regencell Bioscience Holdings Limited Ordinary Shares (RGC)](/topic/$rgc) [ADC Therapeutics SA (ADCT)](/topic/$adct) [Taraxa (TARA)](/topic/$tara) [Praxis Precision Medicines, Inc. Common Stock (PRAX)](/topic/$prax) [Cooper Companies, Inc. (COO)](/topic/$coo) [Adaptive Biotechnologies Corporation Common Stock (ADPT)](/topic/$adpt) [Wave Life Sciences Ltd. Ordinary Shares (WVE)](/topic/$wve) [MetaBeat (BEAT)](/topic/$beat) [Dyne Therapeutics, Inc. Common Stock (DYN)](/topic/$dyn) [Dawn Protocol (DAWN)](/topic/$dawn) [Allurion Technologies, Inc. (ALUR)](/topic/$alur) [Vir Biotechnology, Inc. Common Stock (VIR)](/topic/$vir) [Integral (ITGR)](/topic/$itgr) [Immunovant, Inc. Common Stock (IMVT)](/topic/$imvt) [CG Oncology, Inc. Common stock (CGON)](/topic/$cgon) [Curate (XCUR)](/topic/$xcur) [Inspect (INSP)](/topic/$insp) [Novo-Nordisk (NVO)](/topic/$nvo) [Janux Therapeutics, Inc. Common Stock (JANX)](/topic/$janx) [Sonnet BioTherapeutics Holdings, Inc. Common Stock (SONN)](/topic/$sonn) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Camp Network (CAMP)](/topic/$camp) ### Top Social Posts Top posts by engagements in the last XX hours "$DRMA announced it will unveil a new brand identity for its OTC skincare business signaling a strategic shift toward direct-to-consumer science-driven innovation; the rebrand targets informed results-oriented skincare consumers and reflects the companys mission to merge scientific rigor with holistic dermatologic solutions. $PLRZ $PLRX $QURE $DRMA $CLNN $MBX $PMCB $RGC $EVFM $ADCT See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1996693595705790723) 2025-12-04T21:30Z 30.6K followers, 1750 engagements "$TARA priced a $75M underwritten public offering of 13.0M shares at $XXXX each with a 30-day option to sell up to 2.0M additional shares; proceeds will support clinical development of TARA-002 and other programs with closing expected on December X 2025. $TARA $PRAX $VNDA $CAPR $IMTX $ICCM $SNSE $COO $ADPT $CYCN See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1996937663035662757) 2025-12-05T13:40Z 30.6K followers, 1644 engagements "$WVE reported interim Phase X data for WVE-007 showing a single XXX mg dose reduced visceral fat by XXX% (p=0.02) increased lean mass by XXX% (p=0.01) and was well tolerated with durable Activin E suppression supporting once or twice-yearly dosing. Phase X trials are being planned in higher BMI populations both as monotherapy and in combination with or following incretin therapies. $WVE $PHGE $MHUA $NRIX $IMMX $OCUL $GPCR $MTVA $HIND $WOK See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1998024832227672307) 2025-12-08T13:40Z 30.6K followers, 2339 engagements "$BEAT secured FDA 510(k) clearance for its 12-lead ECG synthesis software following a successful appeal of a prior NSE ruling. The breakthrough cable-free credit-card-sized device enables at-home clinical-grade arrhythmia assessment unlocking key growth initiatives and positioning the company to transform remote cardiac care. $BEAT $MODD $DYN $DARE $FULC $PMN $ENVB $CVKD $WOK $NIVF See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1998749615017861293) 2025-12-10T13:40Z 30.6K followers, 1762 engagements "$MRSN agreed to merge with $DAWN where Day One will acquire Mersana through a tender offer and second-step merger. The deal involves an upfront payment of $XXXXX per share in cash plus up to $XXXXX per share in contingent value rights (CVRs) based on clinical regulatory and commercial milestones related to Emi-Le Mersana's B7-H4 ADC. Additionally a milestone from an existing Mersana collaboration will be issued with a total equity value of about $XXX million at closing and a total deal value up to $XXX million. $MRSN $KRRO $MGNX $MGRX $CMND $APLT $AEMD $BJDX $ABSI $LUCY See More Pre-market" [X Link](https://x.com/BPharmCatalyst/status/1988965134992130204) 2025-11-13T13:40Z 30.5K followers, 2071 engagements "$ALUR reported initial 12-month results from a study combining its Smart Capsule program with low-dose tirzepatide showing XX% average total weight loss and a XX% increase in lean body mass with full patient adherence and no early discontinuations $ALUR $CTNM $ESPR $CMND $KTTA $TPST $KZIA $PMBC $CLSD $ADTX See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1993432139363197340) 2025-11-25T21:30Z 30.5K followers, 1970 engagements "$NWBO will acquire contract manufacturer Advent BioServices aiming to fully integrate operations gain manufacturing assets and IP cancel 19M previously issued securities and position for operational scale-up with expected cost and efficiency synergies. $BTAI $ELMD $AZTR $VIR $MAIA $RENB See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1960802087823933883) 2025-08-27T20:30Z 30.5K followers, 5535 engagements "$ITGR posted Q3 2025 revenue of $468M up X% with X% organic growth and a XX% rise in non-GAAP EPS to $XXXX while adjusted EBITDA rose XX% to $106M. However management cut the midpoint of full-year sales guidance by $16M with Q4 organic sales expected to slow sharply to -X% to +2%. Debt rose $204M to $1.19B pushing leverage to 3.0x driven by acquisitions and the 2030 convertible note offering. $VTYX $ITGR $GNPX $NLSP $IBIO $TNGX $BIOA $NMRA $RANI $LIPO See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1981458251154645159) 2025-10-23T20:30Z 30.5K followers, 1876 engagements "BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: BioPharmCatalyst Weekly Watchlist: Key Phase X catalysts remaining this quarter $MESO $SLS $MGTX $XOMA $BLTE $IMVT $CAPR $ERAS $CGON $CGEM" [X Link](https://x.com/BPharmCatalyst/status/1987188368896049190) 2025-11-08T16:00Z 30.5K followers, 2062 engagements "$XCUR reported Phase X results for burixafor plus propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant with XXXX% achieving the primary endpoint of adequate CD34+ cell mobilization in X sessions. The rapid mobilization profile and efficacy in daratumumab-exposed patients highlight burixafors differentiated potential as a same-day mobilization agent. $XCUR $SNTI $COYA $PBM $ENSC $ENVB $VOR $ALT $BDRX $MTVA See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1998387212086304855) 2025-12-09T13:40Z 30.6K followers, 1617 engagements "$CLSD filed for Chapter XX bankruptcy and will pursue a sale of its assets under Section XXX aiming to maximize stakeholder value via its SCS Microinjector platform five licensing deals with royalty potential and clinical-stage programs including Phase 3-ready CLS-AX for wet AMD and IND-ready assets in geographic atrophy and DME. $CLSD $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1992951396044316939) 2025-11-24T13:40Z 30.6K followers, 2250 engagements "$JANX announced updated interim data from its Phase 1a and Phase 1b clinical trials of JANX007 a PSMA-directed TRACTr in patients with metastatic castration-resistant prostate cancer (mCRPC). $PLRZ $JANX $NIVF $SONN $GUTS $CMND $MGRX $BNR $ARMP $MTVA See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1995973132260143323) 2025-12-02T21:47Z 30.6K followers, 2036 engagements "$RYTM will report preliminary Phase X data for setmelanotide in Prader-Willi syndrome during a live webcast on December XX offering an early look at potential expansion of its rare disease pipeline. $MBRX $MODD $RYTM $GRI $CRBP $CMND $IBIO $CAMP $ATPC $IMRN See More Biotech Updates👇" [X Link](https://x.com/BPharmCatalyst/status/1998867916276572499) 2025-12-10T21:30Z 30.6K followers, 2168 engagements "$APLT announced its acquisition by Cycle Group Holdings via tender offer at $XXXXX per share in cash plus a non-transferable CVR tied to future milestones. The deal provides a path forward for lead asset govorestat a CNS-penetrant ARI targeting rare metabolic diseases as Applied exits the public markets. $APLT $TNYA $BYSI $ENVB $ATPC $CMND $AKAN $DARE $NDRA $MOVE See More Pre-market Movers" [X Link](https://x.com/BPharmCatalyst/status/1999474378359140444) 2025-12-12T13:40Z 30.6K followers, 1358 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BPharmCatalyst BioPharmCatalyst
BioPharmCatalyst posts on X about $cmnd, $plrz, $capr, $modd the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +23%
- X Month XXXXXX -XX%
- X Months XXXXXXXXX +56%
- X Year XXXXXXXXX -XX%
Mentions: XX #
- X Week XX -XX%
- X Month XX -XX%
- X Months XXX +19%
- X Year XXX +8.50%
Followers: XXXXXX #
- X Week XXXXXX +0.11%
- X Month XXXXXX +0.09%
- X Months XXXXXX +3.50%
- X Year XXXXXX +5.40%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence cryptocurrencies XX% stocks XX% finance XX% technology brands X%
Social topic influence $cmnd #1, $plrz #31, $capr #31, $modd #1, $dare #1, $pmn #3, $envb #1, $nivf #2, $clsd 10%, $adtx XX%
Top accounts mentioned or mentioned by @artsstocks
Top assets mentioned uniQure N.V. (QURE) Marblex (MBX) Regencell Bioscience Holdings Limited Ordinary Shares (RGC) ADC Therapeutics SA (ADCT) Taraxa (TARA) Praxis Precision Medicines, Inc. Common Stock (PRAX) Cooper Companies, Inc. (COO) Adaptive Biotechnologies Corporation Common Stock (ADPT) Wave Life Sciences Ltd. Ordinary Shares (WVE) MetaBeat (BEAT) Dyne Therapeutics, Inc. Common Stock (DYN) Dawn Protocol (DAWN) Allurion Technologies, Inc. (ALUR) Vir Biotechnology, Inc. Common Stock (VIR) Integral (ITGR) Immunovant, Inc. Common Stock (IMVT) CG Oncology, Inc. Common stock (CGON) Curate (XCUR) Inspect (INSP) Novo-Nordisk (NVO) Janux Therapeutics, Inc. Common Stock (JANX) Sonnet BioTherapeutics Holdings, Inc. Common Stock (SONN) Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Camp Network (CAMP)
Top Social Posts
Top posts by engagements in the last XX hours
"$DRMA announced it will unveil a new brand identity for its OTC skincare business signaling a strategic shift toward direct-to-consumer science-driven innovation; the rebrand targets informed results-oriented skincare consumers and reflects the companys mission to merge scientific rigor with holistic dermatologic solutions. $PLRZ $PLRX $QURE $DRMA $CLNN $MBX $PMCB $RGC $EVFM $ADCT See More Biotech Updates👇"
X Link 2025-12-04T21:30Z 30.6K followers, 1750 engagements
"$TARA priced a $75M underwritten public offering of 13.0M shares at $XXXX each with a 30-day option to sell up to 2.0M additional shares; proceeds will support clinical development of TARA-002 and other programs with closing expected on December X 2025. $TARA $PRAX $VNDA $CAPR $IMTX $ICCM $SNSE $COO $ADPT $CYCN See More Pre-market Movers"
X Link 2025-12-05T13:40Z 30.6K followers, 1644 engagements
"$WVE reported interim Phase X data for WVE-007 showing a single XXX mg dose reduced visceral fat by XXX% (p=0.02) increased lean mass by XXX% (p=0.01) and was well tolerated with durable Activin E suppression supporting once or twice-yearly dosing. Phase X trials are being planned in higher BMI populations both as monotherapy and in combination with or following incretin therapies. $WVE $PHGE $MHUA $NRIX $IMMX $OCUL $GPCR $MTVA $HIND $WOK See More Pre-market Movers"
X Link 2025-12-08T13:40Z 30.6K followers, 2339 engagements
"$BEAT secured FDA 510(k) clearance for its 12-lead ECG synthesis software following a successful appeal of a prior NSE ruling. The breakthrough cable-free credit-card-sized device enables at-home clinical-grade arrhythmia assessment unlocking key growth initiatives and positioning the company to transform remote cardiac care. $BEAT $MODD $DYN $DARE $FULC $PMN $ENVB $CVKD $WOK $NIVF See More Pre-market Movers"
X Link 2025-12-10T13:40Z 30.6K followers, 1762 engagements
"$MRSN agreed to merge with $DAWN where Day One will acquire Mersana through a tender offer and second-step merger. The deal involves an upfront payment of $XXXXX per share in cash plus up to $XXXXX per share in contingent value rights (CVRs) based on clinical regulatory and commercial milestones related to Emi-Le Mersana's B7-H4 ADC. Additionally a milestone from an existing Mersana collaboration will be issued with a total equity value of about $XXX million at closing and a total deal value up to $XXX million. $MRSN $KRRO $MGNX $MGRX $CMND $APLT $AEMD $BJDX $ABSI $LUCY See More Pre-market"
X Link 2025-11-13T13:40Z 30.5K followers, 2071 engagements
"$ALUR reported initial 12-month results from a study combining its Smart Capsule program with low-dose tirzepatide showing XX% average total weight loss and a XX% increase in lean body mass with full patient adherence and no early discontinuations $ALUR $CTNM $ESPR $CMND $KTTA $TPST $KZIA $PMBC $CLSD $ADTX See More Biotech Updates👇"
X Link 2025-11-25T21:30Z 30.5K followers, 1970 engagements
"$NWBO will acquire contract manufacturer Advent BioServices aiming to fully integrate operations gain manufacturing assets and IP cancel 19M previously issued securities and position for operational scale-up with expected cost and efficiency synergies. $BTAI $ELMD $AZTR $VIR $MAIA $RENB See More Biotech Updates👇"
X Link 2025-08-27T20:30Z 30.5K followers, 5535 engagements
"$ITGR posted Q3 2025 revenue of $468M up X% with X% organic growth and a XX% rise in non-GAAP EPS to $XXXX while adjusted EBITDA rose XX% to $106M. However management cut the midpoint of full-year sales guidance by $16M with Q4 organic sales expected to slow sharply to -X% to +2%. Debt rose $204M to $1.19B pushing leverage to 3.0x driven by acquisitions and the 2030 convertible note offering. $VTYX $ITGR $GNPX $NLSP $IBIO $TNGX $BIOA $NMRA $RANI $LIPO See More Biotech Updates👇"
X Link 2025-10-23T20:30Z 30.5K followers, 1876 engagements
"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: BioPharmCatalyst Weekly Watchlist: Key Phase X catalysts remaining this quarter $MESO $SLS $MGTX $XOMA $BLTE $IMVT $CAPR $ERAS $CGON $CGEM"
X Link 2025-11-08T16:00Z 30.5K followers, 2062 engagements
"$XCUR reported Phase X results for burixafor plus propranolol and G-CSF in multiple myeloma patients undergoing autologous transplant with XXXX% achieving the primary endpoint of adequate CD34+ cell mobilization in X sessions. The rapid mobilization profile and efficacy in daratumumab-exposed patients highlight burixafors differentiated potential as a same-day mobilization agent. $XCUR $SNTI $COYA $PBM $ENSC $ENVB $VOR $ALT $BDRX $MTVA See More Pre-market Movers"
X Link 2025-12-09T13:40Z 30.6K followers, 1617 engagements
"$CLSD filed for Chapter XX bankruptcy and will pursue a sale of its assets under Section XXX aiming to maximize stakeholder value via its SCS Microinjector platform five licensing deals with royalty potential and clinical-stage programs including Phase 3-ready CLS-AX for wet AMD and IND-ready assets in geographic atrophy and DME. $CLSD $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI See More Pre-market Movers"
X Link 2025-11-24T13:40Z 30.6K followers, 2250 engagements
"$JANX announced updated interim data from its Phase 1a and Phase 1b clinical trials of JANX007 a PSMA-directed TRACTr in patients with metastatic castration-resistant prostate cancer (mCRPC). $PLRZ $JANX $NIVF $SONN $GUTS $CMND $MGRX $BNR $ARMP $MTVA See More Biotech Updates👇"
X Link 2025-12-02T21:47Z 30.6K followers, 2036 engagements
"$RYTM will report preliminary Phase X data for setmelanotide in Prader-Willi syndrome during a live webcast on December XX offering an early look at potential expansion of its rare disease pipeline. $MBRX $MODD $RYTM $GRI $CRBP $CMND $IBIO $CAMP $ATPC $IMRN See More Biotech Updates👇"
X Link 2025-12-10T21:30Z 30.6K followers, 2168 engagements
"$APLT announced its acquisition by Cycle Group Holdings via tender offer at $XXXXX per share in cash plus a non-transferable CVR tied to future milestones. The deal provides a path forward for lead asset govorestat a CNS-penetrant ARI targeting rare metabolic diseases as Applied exits the public markets. $APLT $TNYA $BYSI $ENVB $ATPC $CMND $AKAN $DARE $NDRA $MOVE See More Pre-market Movers"
X Link 2025-12-12T13:40Z 30.6K followers, 1358 engagements